OraSure Technologies (NASDAQ:OSUR) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.
Other equities research analysts have also issued reports about the company. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and set a $23.00 price objective on shares of OraSure Technologies in a research note on Friday, October 20th. Finally, ValuEngine lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. OraSure Technologies has an average rating of “Buy” and an average target price of $19.65.
OraSure Technologies (NASDAQ:OSUR) opened at $21.71 on Friday. The stock has a market capitalization of $1,320.00, a price-to-earnings ratio of 41.75, a price-to-earnings-growth ratio of 4.76 and a beta of 1.27. OraSure Technologies has a one year low of $8.39 and a one year high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.09. The firm had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The firm’s quarterly revenue was up 31.0% on a year-over-year basis. During the same period last year, the company posted $0.11 EPS. sell-side analysts predict that OraSure Technologies will post 0.43 EPS for the current year.
In related news, Director Mara G. Aspinall acquired 5,000 shares of OraSure Technologies stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average cost of $14.23 per share, with a total value of $71,150.00. Following the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.40% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of OraSure Technologies by 6.9% during the 2nd quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after acquiring an additional 106,326 shares in the last quarter. USA Financial Portformulas Corp boosted its stake in shares of OraSure Technologies by 31.0% during the 2nd quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after acquiring an additional 13,421 shares in the last quarter. 361 Capital LLC boosted its position in shares of OraSure Technologies by 59.9% in the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after buying an additional 10,107 shares during the period. Voya Investment Management LLC boosted its position in shares of OraSure Technologies by 179.4% in the second quarter. Voya Investment Management LLC now owns 78,325 shares of the medical instruments supplier’s stock worth $1,352,000 after buying an additional 50,287 shares during the period. Finally, Macquarie Group Ltd. acquired a new stake in shares of OraSure Technologies in the second quarter worth $892,000. 94.43% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “OraSure Technologies (OSUR) Rating Increased to Strong-Buy at BidaskClub” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/20/orasure-technologies-osur-rating-increased-to-strong-buy-at-bidaskclub.html.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.